{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T05:52:22Z","timestamp":1745560342270,"version":"3.40.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40259-022-00532-y","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:05:41Z","timestamp":1652699141000},"page":"337-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine"],"prefix":"10.1007","volume":"36","author":[{"given":"Fidel Dominique Festin","family":"Ambat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-9905","authenticated-orcid":false,"given":"Enrico","family":"Bentivegna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-4128","authenticated-orcid":false,"given":"Paolo","family":"Martelletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"532_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-021-01362-z","volume":"22","author":"H Thomas","year":"2021","unstructured":"Thomas H, Kothari SF, Hus\u00f8y A, et al. The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries. J Headache Pain. 2021;22:153. https:\/\/doi.org\/10.1186\/s10194-021-01362-z.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-021-01349-w","volume":"22","author":"V Obermeier","year":"2021","unstructured":"Obermeier V, Murawski M, Heinen F, Landgraf MN, Straube A, von Kries R, Ruscheweyh R. Total health insurance costs in children with a migraine diagnosis compared to a control group. J Headache Pain. 2021;22(1):140. https:\/\/doi.org\/10.1186\/s10194-021-01349-w.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-020-01144-z","volume":"21","author":"LP Wong","year":"2020","unstructured":"Wong LP, Alias H, Bhoo-Pathy N, Chung I, Chong YC, Kalra S, Shah ZUBS. Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. J Headache Pain. 2020;21(1):68. https:\/\/doi.org\/10.1186\/s10194-020-01144-z (Erratum in: J Headache Pain. 2020 Aug 18;21(1):104).","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, Azuma Y, Dodick DW. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22(1):29. https:\/\/doi.org\/10.1186\/s10194-021-01243-5.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional National Health and Wellness Survey. J Headache Pain. 2020;21(1):110. https:\/\/doi.org\/10.1186\/s10194-020-01180-9.","journal-title":"J Headache Pain"},{"key":"532_CR6","doi-asserted-by":"publisher","unstructured":"Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. 2022;1\u201318. https:\/\/doi.org\/10.1007\/s40259-022-00530-0.","DOI":"10.1007\/s40259-022-00530-0"},{"key":"532_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s10194-021-01335-2","volume":"22","author":"F Vandervorst","year":"2021","unstructured":"Vandervorst F, Van Deun L, Van Dycke A, et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22:128. https:\/\/doi.org\/10.1186\/s10194-021-01335-2.","journal-title":"J Headache Pain"},{"key":"532_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain. 2020;21:76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5.","journal-title":"J Headache Pain"},{"key":"532_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-021-01252-4","volume":"22","author":"S Sacco","year":"2021","unstructured":"Sacco S, Lampl C, Maassen van den Brink A, et al. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain. 2021;22:39. https:\/\/doi.org\/10.1186\/s10194-021-01252-4.","journal-title":"J Headache Pain"},{"key":"532_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s10194-019-1009-9","volume":"20","author":"P Martelletti","year":"2019","unstructured":"Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain. 2019;20:60. https:\/\/doi.org\/10.1186\/s10194-019-1009-9.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1080\/13696998.2021.1953301","volume":"24","author":"P Vo","year":"2021","unstructured":"Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Tiwari S, Joshi P, Ferraris M. Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened\/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 2021;24(1):900\u20137. https:\/\/doi.org\/10.1080\/13696998.2021.1953301.","journal-title":"J Med Econ"},{"issue":"1","key":"532_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-021-01269-9","volume":"22","author":"TJ Steiner","year":"2021","unstructured":"Steiner TJ, Linde M, Schnell-Inderst P. A universal outcome measure for headache treatments, care-delivery systems and economic analysis. J Headache Pain. 2021;22(1):63. https:\/\/doi.org\/10.1186\/s10194-021-01269-9.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1080\/13696998.2021.1925557","volume":"24","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Schwedt TJ, Vo P, Ritrovato D, Reilly MC, Naclerio M, Ranjan P, Kleebach J, Joshi P. Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. J Med Econ. 2021;24(1):717\u201326. https:\/\/doi.org\/10.1080\/13696998.2021.1925557.","journal-title":"J Med Econ"},{"key":"532_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-021-01281-z","volume":"22","author":"V Caponnetto","year":"2021","unstructured":"Caponnetto V, Deodato M, Robotti M, et al. Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain. 2021;22:71. https:\/\/doi.org\/10.1186\/s10194-021-01281-z.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y, Cao H. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 2020;21(1):53. https:\/\/doi.org\/10.1186\/s10194-020-01117-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A. A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain. 2019;20(1):41. https:\/\/doi.org\/10.1186\/s10194-019-0993-0.","journal-title":"J Headache Pain"},{"key":"532_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2022.2045954","author":"E Bentivegna","year":"2022","unstructured":"Bentivegna E, Tassorelli C, De Icco R, Sances G, Martelletti P. Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Rev Neurother. 2022. https:\/\/doi.org\/10.1080\/14737175.2022.2045954.","journal-title":"Expert Rev Neurother."},{"issue":"1","key":"532_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s10194-020-01094-6","volume":"21","author":"A Negro","year":"2020","unstructured":"Negro A, Spuntarelli V, Sciattella P, Martelletti P. Rapid referral for headache management from emergency department to headache centre: four years data. J Headache Pain. 2020;21(1):25. https:\/\/doi.org\/10.1186\/s10194-020-01094-6.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-019-1068-y","volume":"20","author":"A Negro","year":"2019","unstructured":"Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20(1):120. https:\/\/doi.org\/10.1186\/s10194-019-1068-y.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","volume":"22","author":"P McAllister","year":"2021","unstructured":"McAllister P, Lamerato L, Krasenbaum LJ, Cohen JM, Tangirala K, Thompson S, Driessen M, Casciano J, Dotiwala Z, Mauskop A. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22(1):156. https:\/\/doi.org\/10.1186\/s10194-021-01358-9.","journal-title":"J Headache Pain"},{"issue":"1","key":"532_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","volume":"22","author":"F Vernieri","year":"2021","unstructured":"Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d\u2019Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021;22(1):154. https:\/\/doi.org\/10.1186\/s10194-021-01363-y.","journal-title":"J Headache Pain"},{"key":"532_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2021.2003127","volume":"2","author":"SA Foster","year":"2021","unstructured":"Foster SA, Hoyt M, Ye W, Mason O, Ford JH. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes. Curr Med Res Opin. 2021;2:1\u20138. https:\/\/doi.org\/10.1080\/03007995.2021.2003127.","journal-title":"Curr Med Res Opin"},{"key":"532_CR23","doi-asserted-by":"publisher","unstructured":"Takahashi TT, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S, Guglielmetti M, Maria De Marco C, Dutordoir C, Colangeli E, Fuccaro M, Di Lenola D, Spuntarelli V, Pilati L, Di Marco S, Van Dycke A, Abdullahi RA, Maassen van den Brink A, Martelletti P; European Headache Federation School of Advanced Studies (EHF-SAS). Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain. 2021;22(1):32. doi: https:\/\/doi.org\/10.1186\/s10194-021-01224-8. Erratum in: J Headache Pain. 2021 Jul 5;22(1):64","DOI":"10.1186\/s10194-021-01224-8"},{"issue":"6","key":"532_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2021.1907342","volume":"20","author":"P Martelletti","year":"2021","unstructured":"Martelletti P, Luciani M, Spuntarelli V, Bentivegna E. Deprescribing in migraine. Expert Opin Drug Saf. 2021;20(6):623\u20135. https:\/\/doi.org\/10.1080\/14740338.2021.1907342.","journal-title":"Expert Opin Drug Saf"},{"key":"532_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2049236","author":"S Benemei","year":"2022","unstructured":"Benemei S, Bentivegna E, Martelletti P. Positioning the new drugs for migraine. Expert Opin Drug Metab Toxicol. 2022. https:\/\/doi.org\/10.1080\/17425255.2022.2049236.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"532_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-021-01305-8","volume":"22","author":"M Tinelli","year":"2021","unstructured":"Tinelli M, Leonardi M, Paemeleire K, Raggi A, Mitsikostas D, de la Torre ER, Steiner TJ, European Brain Council Value of Treatment Headache Working Group, the European Headache Federation, the European Migraine and Headache Alliance and Lifting The Burden: the Global Campaign against Headache. Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain. 2021;22(1):90. https:\/\/doi.org\/10.1186\/s10194-021-01305-8.","journal-title":"J Headache Pain"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00532-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00532-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00532-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:16:02Z","timestamp":1744715762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00532-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["532"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00532-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"type":"print","value":"1173-8804"},{"type":"electronic","value":"1179-190X"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"7 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors disclose no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors contributed equally to the writing of this commentary, and approved the final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}